VC
FTH

Vivo Capital’s Faeth Therapeutics FTH Stock Holding History

Vivo Capital’s Portfolio FTH Stock Details FTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$22.8M Buy
+722,020
New +$14.4M 1.89% 19

Other funds holding FTH

CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
SC
Stempoint Capital New York $522M AUM 281.95% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Vivo Capital's FTH Position: Q1 2026 in Review

Vivo Capital opened a new position in Faeth Therapeutics (FTH) in Q1 2026: 722,020 shares worth $22.8M. The stake represents 1.89% of the portfolio and ranks #19 among its holdings.

30 funds tracked by Wall St. Rank hold FTH as of Q1 2026.

  • Vivo Capital held 722,020 shares of Faeth Therapeutics worth $22.8M as of Q1 2026.
  • Faeth Therapeutics was a new Vivo Capital position in Q1 2026.
  • Faeth Therapeutics made up 1.89% of Vivo Capital's portfolio in Q1 2026, its #19 holding.
  • 30 funds tracked by Wall St. Rank held Faeth Therapeutics as of Q1 2026.

Based on Vivo Capital's 13F filing for Q1 2026, filed 15 May 2026.